• sense clinically
  • think mechanistically
  • act interdisciplinarily
  • treat innovatively

PD Dr. med. Frederik Damm

Research Group Leader
Department of Hematology, Oncology, and Tumor Immunology
Charité - Universitätsmedizin Berlin
Augustenburgr Platz 1
13353 Berlin

E-Mail: frederik.damm@ charite.de
https://haema-onko-cvk.charite.de/forschung/arbeitsgruppen/ag_damm/

Scientific Scope

The research group of Frederik Damm focuses on genetic events defining early steps during leukemo-/ lymphomagenesis using several molecular biology techniques. Combinations of various sequencing technologies using bulk and single-cell approaches help to develop novel models of precision oncology.  A broad national and international collaborating network supports investigations of rare tumor entities and/or molecularly defined subgroups.

Selected References

  • Mylonas E, Yoshida K, Frick M, ..., Damm F. Single-cell analysis based dissection of clonality in myelofibrosis. Nature Communications. 2020; 11(1):73
  • Christen F, Hoyer K, Yoshida K, ..., Damm F. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood. 2019; 133(10): 1140-1151
  • Frick M, Chan W, Arends CM, ..., Damm F. Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology. 2019; 37(5): 375-385
  • Arends CM, Galan-Sousa J, Hoyer K, …, Damm F. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia. 2018; 32(9): 1908-1919
  • Young E, Noerenberg D, Mansouri L, ..., Damm F. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. Leukemia. 2017; 31:1547–1554
  • Mansouri L, Noerenberg D, Young E, ..., Damm F. Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood. 2016;128: 2666–2670